Posted: February 21, 2024 at 2:34 am
Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells News-Medical.Net
See original here:
Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net
Posted: February 21, 2024 at 2:34 am
Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors Pink Sheet
See the article here:
Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet
Posted: February 21, 2024 at 2:34 am
Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits Medriva
Read the original:
Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva
Posted: February 21, 2024 at 2:34 am
What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today India Today
See the rest here:
What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today
Posted: February 21, 2024 at 2:34 am
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... Yahoo Finance
Posted: February 21, 2024 at 2:34 am
Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics Conference Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics Conference
More:
PharmAla Data to be Published in ACS Chemical Neuroscience
Posted: February 21, 2024 at 2:34 am
PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
Posted: February 21, 2024 at 2:34 am
The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader
Read the rest here:
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
Posted: February 21, 2024 at 2:34 am
Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection
Posted: February 21, 2024 at 2:34 am
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.
Continued here:
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
